Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie Inc., Amgen, AstraZeneca Pharmaceuticals LP and Acerta Pharma, and Kite, A Gilead Company

Year in Review™: Reflecting on Recent Evidence for the Treatment of Hematologic Malignancies

Release Date: February 28, 2018
Expiration Date: February 28, 2019
Media: Internet - based


Activity Overview

This online activity features an expert panel discussion of noteworthy data presented at major society meetings in 2017. These findings focus on advances in specific therapeutic approaches to the treatment and management of hematologic malignancies, such as targeted therapies, immunotherapy, chemotherapy, and personalizing care through diagnostic testing.

The format for today’s YEAR IN REVIEW™ will include 5 modules of didactic presentations and interactive discussion among our panel of experts, providing insight into recent advances in chronic leukemias, acute leukemias, B-cell malignancies, myeloproliferative neoplasms (MPNs), and CAR T-cell therapies. Expert perspective will be provided on the clinical application of these data, and the future direction of the hematologic malignancy treatment landscape.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie Inc., Amgen, AstraZeneca Pharmaceuticals LP and Acerta Pharma, and Kite, A Gilead Company

CME/CE Activity Table of Contents

  • Introduction
  • Module 1: Chronic Lymphocytic Leukemias
  • Module 2: Acute Leukemias
  • Module 3: B-Cell and Plasma Cell Malignancies
  • Module 4: Myeloproliferative Neoplasms
  • Module 5: CAR T-Cell Therapy and Final Remarks

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and hematologists involved in the treatment and management of patients with hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Outline evolving management strategies that can inform clinical decision making in the treatment of hematologic malignancies
  • Integrate clinical trial results into the management of case-based scenarios for hematologic malignancies
  • Describe approaches to proactively identify and mitigate treatment-related adverse events in patients with leukemia, lymphoma, and multiple myeloma
  • Explain the clinical significance of emerging data by placing recent findings into the context of evolving treatment paradigms for hematologic malignancies

Faculty, Staff, and Planners' Disclosures


Daniel J. DeAngelo, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Institute Physician, Adult Leukemia Program
Dana-Farber Cancer Institute
Boston, MA

Disclosure:Grant/Research: Blueprint Pharmaceuticals; Consultant: Amgen, BMS, Incyte, Jazz, Novartis, Pfizer, Takeda, Shire


Jacqueline Barrientos, MD, MS
Associate Professor, Division of Hematology and Medical Oncology
Department of Medicine
Hofstra Northwell School of Medicine
Hempstead, NY

Disclosure:Consultant: Grant/Research: Gilead, Pharmacyclics/AbbVie; Consultant: Gilead, Pharmacyclics/AbbVie; Other ‒ Honoraria: Janssen

Brian T. Hill, MD, PhD
Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Assistant Professor, Cleveland Clinic
Cleveland, OH

Disclosure:Grant/Research Support: Kite Pharma Inc., Seattle Genetics; Consultant: Genentech, AbbVie, Pharmacyclics, Gilead, Novartis; Other ‒ Advisory Board: Seattle Genetics

Alexander Perl, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosure:Consultant/Advisory Board: Astellas, Daiichi Sankyo, Arog, Novartis, Actinium Pharmaceuticals, Seattle Genetics

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By